Phase 2 Study of KHK4577

Summary

This study is an randomized double-blind placebo-controlled study to evaluate the efficacy and the safety of oral KHK4577 for 6 weeks in patients with atopic dermatitis. Pharmacokinetics of KHK4577 will also be assessed.

Timeline

Start

2013-11

Primary completion

2014-12

Completion

2014-12

Drugs

Indications